Connell Consulting
Remember me:
Skip Navigation Links
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.

Posted on: 26/09/2011

Latest news stories

Core Capital Partners has sold SPL Services, which trades as PDP Couriers to Cryo International, delivering a 2.4x money return the private equity firm.
Lord Crisp’s commission on acute adult psychiatric care has said that no acutely ill patient should have to travel a long distance for non-specialist treatment, from October 2017.
Circle Holdings, the parent company of private hospital group Circle Health, has “exceeded management expectations” for both revenue and ebitda.
Specialist care provider Cambian’s latest trading statement indicates its ebitda will be £46 million for the year-ended 31 December 2015 – 6% below its October 2015 revised forecast of “not less than £49 million”.
Almost four in 10 people are willing to have a GP consultation through an app, a survey has found.

2016 is due to be a dramatic year for care providers. David Waller reviews the social care status quo

The dynamics have changed in the care home sector. Ploy Radford finds that it is not just a question of scale anymore
Investors and customers can’t seem to get enough of Audley Retirement Villages. Ploy Radford talks to CEO Nick Sanderson to find out more

Christie + Co

In a tough home care environment Saga couldn’t get rid of Allied Healthcare fast enough. Aurelius tells HealthInvestor why it was willing to take on the risky investment
Renaissance Care chairman Robert Kilgour takes issue with the Scottish government’s handling of care
When 2 billion people officially do not exist, how do you solve the ensuing healthcare issues? Simprints offers an answer
Leonid Shapiro of Candesic examines what the latest government legislation means for the social care sector
Optegra Eye Health Care has just launched a new flagship hospital near London’s Harley Street as part of its plan to establish itself as a global eye care specialist, Sunniva Davies-Rommetveit and Ploy Radford find out more

Click here to search all feature articles